Investigating the effects of cold atmospheric plasma on peritoneal tumor tissue

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the effects of cold atmospheric plasma (CAP) on tumor tissue in patients with peritoneal metastases undergoing surgery. Tumor nodules will be treated with varying durations and intensities of CAP prior to surgical removal. The resected nodules will then be analyzed to assess tumor vitality and the potential impact of CAP treatment. This innovative approach seeks to provide insights into the efficacy of CAP in targeting tumor cells.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Patients with peritoneal metastases undergoing surgery (CRS, debulking), irrespective of the origin. Potential cancer types include ovarian cancer, colorectal cancer, and malignant peritoneal mesothelioma
* Written informed consent
* Age ≥ 18 years.

Where it's running

• UZ Ghent
  Ghent, East-Flanders, Belgium Recruiting

Study contacts

• Study coordinator: Wim Ceelen, professor
• Email: wim.ceelen@ugent.be
• Phone: +3293326251

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MT027 cell injections for advanced peritoneal tumors

  We will try MT027 cell injections in adults with advanced primary or secondary peritoneal tumors to see if they are safe and show early signs of benefit.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07004647

• Quadruplet induction plus autologous transplant followed by teclistamab maintenance for plasma cell leukemia

  This phase 2 trial tests whether adding teclistamab as consolidation after autologous stem cell transplant improves overall survival for patients with plasma cell leukemia compared with the standard D-KRd consolidation.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · La Jolla, California and 10 other locations · NCT07605416

• Autologous stem‑cell transplant plus BCMA CAR‑T for ultra‑high‑risk multiple myeloma

  This test combines an autologous stem‑cell transplant with BCMA CAR‑T therapy to see if it helps adults (18–70) with ultra‑high‑risk multiple myeloma who are eligible for transplant.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07109323

• CT0596 CAR-T treatment for plasma cell leukemia

  The study will try CT0596 CAR‑T cell therapy in adults with plasma cell leukemia to see if it is safe and can shrink the disease.

  Recruiting Early Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06988059

• Observational study on immunotherapy for multiple myeloma in Norway

  This study looks at how well new immunotherapy treatments for multiple myeloma work and what side effects they may cause for patients in Norway.

  Recruiting St. Olavs Hospital · Arendal and 22 other locations · NCT06855121

• Go-slow isatuximab and dexamethasone with later lenalidomide for ultra-frail multiple myeloma patients

  This trial will try a gentle, phased start of isatuximab and dexamethasone, adding lenalidomide later, for newly diagnosed, ultra-frail adults with multiple myeloma or plasma cell leukemia to help them stay on treatment and feel better.

  Recruiting Phase 2 University of Utah · Chicago, Illinois and 1 other locations · NCT06517017

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.